PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTalimogene laherparepvec
Imlygic(talimogene laherparepvec)
Imlygic (talimogene laherparepvec) is a gene pharmaceutical. Talimogene laherparepvec was first approved as Imlygic on 2015-10-27. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Imlygic
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Talimogene laherparepvec
Tradename
Proper name
Company
Number
Date
Products
ImlygicTalimogene laherparepvecAmgenA-125518 RX2015-10-27
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
imlygicBiologic Licensing Application2025-04-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
melanomaD008545
Agency Specific
FDA
EMA
Expiration
Code
talimogene laherparepvec, Imlygic, Amgen Inc.
2122-10-27Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01X: Other antineoplastic agents in atc
L01XL: Antineoplastic cell and gene therapy agents
L01XL02: Talimogene laherparepvec
HCPCS
Code
Description
J9325
Injection, talimogene laherparepvec, per 1 million plaque forming units
Clinical
Clinical Trials
54 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD008545382315
CarcinomaD002277C80.04216
Squamous cell carcinomaD0022941113
Head and neck neoplasmsD006258112
Squamous cell neoplasmsD018307112
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50414
SarcomaD012509244
NeoplasmsD009369C80223
Triple negative breast neoplasmsD064726212
Invasive hydatidiform moleD002820D39.2212
Lung neoplasmsD008175C34.90111
Pleural effusionD010996J90111
Malignant pleural effusionD016066J91.0111
Ductal carcinoma breastD018270111
Ductal carcinomaD044584111
Show 7 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD01517911
Neoplasm metastasisD009362EFO_000970811
Squamous cell carcinoma of head and neckD00007719511
Transitional cell carcinomaD00229511
Pancreatic neoplasmsD010190EFO_0003860C2511
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_000054411
Communicable diseasesD00314111
Herpes simplexD006561B0011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTalimogene laherparepvec
INNtalimogene laherparepvec
Description
Talimogene laherparepvec, sold under the brand name Imlygic, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the recipient's cancer. The final four year analysis from the pivotal phase 3 study upon which TVEC was approved by the FDA showed a 31.5% response rate with a 16.9% complete response (CR) rate. There was also a substantial and statistically significant survival benefit in patients with earlier metastatic disease (stages IIIb-IVM1a) and in patients who hadn't received prior systemic treatment for melanoma. The earlier stage group had a reduction in the risk of death of approximately 50% with one in four patients appearing to have met, or be close to be reaching, the medical definition of cure. Real world use of talimogene laherparepvec have shown response rates of up to 88.5% with CR rates of up to 61.5%.
Classification
Gene
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID1187560-31-1
RxCUI1721264
ChEMBL IDCHEMBL2108727
ChEBI ID
PubChem CID
DrugBankDB13896
UNII ID07730V90L6 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,713 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,394 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use